ADVANCE-ID is pleased to share a significant milestone in the Phase 2b RIV-CARE clinical trial, following BioVersys’ announcement on 29 October 2026 of the first patient first visit in the study. RIV-CARE is an open-label Phase …
ADVANCE-ID, in collaboration with the World Health Organization (WHO), successfully organised the ADVANCE-ID Clinical Trial Workshop 2026 from 31 August to 2 September 2026 in Singapore. The two-and-a-half-day workshop brought together researchers and international experts to …
ADVANCE-ID is pleased to announce the launch of ADVANCEing CLINICAL TRIALS: a statistical guIDe, a free online educational series designed to strengthen researchers’ understanding of statistical principles and methodologies in clinical trial design and analysis. Supported …
ADVANCE-ID marked a significant milestone on 31 August 2026 with the official launch of its designation as a World Health Organization (WHO) Collaborating Centre for Clinical Trials, reinforcing its commitment to strengthening clinical research capacity and …
ADVANCE-ID celebrates the publication of its first study, the ACORN-HAI (A Clinically-Oriented Antimicrobial Resistance Surveillance Network – Healthcare-Associated Infections) study, in The Lancet Infectious Diseases on 21 August 2026. This multicentre prospective cohort study enrolled more …
We are pleased to announce that Dr Mo Yin has been appointed as the Director of ADVANCE-ID, with effect from 1 July 2026. An Infectious Diseases physician and clinician-scientist, Dr Mo Yin has served as Deputy …
Our ADVANCE-ID team had a wonderful time at ESCMID Global 2026, where we shared our latest research and connected with colleagues from around the world. Throughout the congress, our researchers presented work spanning antimicrobial resistance (AMR), …
Thank you for your interest in the REACH Asia Forum on Community Engagement! The recordings below feature our Expert Talks, with speakers sharing perspectives from across the region on strengthening community engagement and participation in health …
Seeking therapeutics for infections caused by Gram-negative pathogens and diagnostics for Salmonella Typhi (BOSTON: November 19, 2025) – Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today updated eligibility criteria to support its second call of the …
Join us on 8–9 Dec 2025 for the REACH Asia Forum on Community Engagement! Hear from experts and community leaders across the region on strengthening community engagement and participation in health research.Register at 🔗 https://ad-id.co/reach2025